Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermatophagoides injective allergoid
- Development stage
- Unknown
- Lead developer
- Lofarma
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Dermatophagoides injective allergoid is an investigational subcutaneous allergen immunotherapy (AIT) product developed by LOFARMA S.p.A. for the treatment of respiratory allergies, including allergic rhinitis, rhinoconjunctivitis, and asthma. The active component consists of house dust mite allergens (typically from *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*) that have been chemically modified into allergoids. This modification reduces the allergens' IgE-binding capacity, thereby decreasing the risk of immediate allergic reactions while preserving their ability to stimulate the immune system toward tolerance. The allergoids are adsorbed onto calcium phosphate, which acts as an adjuvant to enhance the therapeutic effect. The drug is administered via subcutaneous injection and aims to desensitize patients by modulating the Th2-mediated allergic immune response.
- Other names
- Dermatophagoides injective allergoid adsorbed on calcium phosphateHouse dust mite injective allergoidAllergoid Injective
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)House dust mite–specific B-cell receptor
Beyond the preview
Go deeper on Dermatophagoides injective allergoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dermatophagoides injective allergoid.